Human Neural Stem Cells Differentiate and Promote Locomotor Recovery in an Early Chronic Spinal Cord Injury NOD-scid Mouse Model
Overview
Affiliations
Background: Traumatic spinal cord injury (SCI) results in partial or complete paralysis and is characterized by a loss of neurons and oligodendrocytes, axonal injury, and demyelination/dysmyelination of spared axons. Approximately 1,250,000 individuals have chronic SCI in the U.S.; therefore treatment in the chronic stages is highly clinically relevant. Human neural stem cells (hCNS-SCns) were prospectively isolated based on fluorescence-activated cell sorting for a CD133(+) and CD24(-/lo) population from fetal brain, grown as neurospheres, and lineage restricted to generate neurons, oligodendrocytes and astrocytes. hCNS-SCns have recently been transplanted sub-acutely following spinal cord injury and found to promote improved locomotor recovery. We tested the ability of hCNS-SCns transplanted 30 days post SCI to survive, differentiate, migrate, and promote improved locomotor recovery.
Methods And Findings: hCNS-SCns were transplanted into immunodeficient NOD-scid mice 30 days post spinal cord contusion injury. hCNS-SCns transplanted mice demonstrated significantly improved locomotor recovery compared to vehicle controls using open field locomotor testing and CatWalk gait analysis. Transplanted hCNS-SCns exhibited long-term engraftment, migration, limited proliferation, and differentiation predominantly to oligodendrocytes and neurons. Astrocytic differentiation was rare and mice did not exhibit mechanical allodynia. Furthermore, differentiated hCNS-SCns integrated with the host as demonstrated by co-localization of human cytoplasm with discrete staining for the paranodal marker contactin-associated protein.
Conclusions: The results suggest that hCNS-SCns are capable of surviving, differentiating, and promoting improved locomotor recovery when transplanted into an early chronic injury microenvironment. These data suggest that hCNS-SCns transplantation has efficacy in an early chronic SCI setting and thus expands the "window of opportunity" for intervention.
Walling I, Baumgartner S, Patel M, Crone S Front Neural Circuits. 2025; 18:1480291.
PMID: 39911754 PMC: 11794311. DOI: 10.3389/fncir.2024.1480291.
de Araujo A, Santos G, Marcon R, Nicola M, Pereira M, Sanchez F Clinics (Sao Paulo). 2025; 80:100579.
PMID: 39889361 PMC: 11833352. DOI: 10.1016/j.clinsp.2025.100579.
Wen R, Long G, He X, Zhang K, Ma W, Shen Y Theranostics. 2025; 15(4):1552-1569.
PMID: 39816688 PMC: 11729559. DOI: 10.7150/thno.103033.
Induced Neural Stem Cell Transplantation in Spinal Cord Injury: Present Status and Next Steps.
Jung J, Jeong J, Ko M, Lee B, Kwon W, Jeon S Korean J Neurotrauma. 2025; 20(4):234-245.
PMID: 39803345 PMC: 11711022. DOI: 10.13004/kjnt.2024.20.e45.
Roman A, Huntemer-Silveira A, Waldron M, Khalid Z, Blake J, Parr A Cell Transplant. 2024; 33():9636897241241998.
PMID: 38590295 PMC: 11005494. DOI: 10.1177/09636897241241998.